 | Up a level |
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Schoenenberger, Lukas Klaus; Schmid, Alexander; Tanase, Radu; Beck, Mathias; Schwaninger, Markus (2021). Structural Analysis of System Dynamics Models Simulation Modelling Practice and Theory, 110, p. 102333. Elsevier 10.1016/j.simpat.2021.102333
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Bilger, Jana Franziska; Pletscher, Mark; Müller, Tobias Benjamin (2024). Separating the wheat from the chaff: How to measure hospital quality in routine data? Health Services Research, 59(2), pp. 1-10. Wiley Online Library 10.1111/1475-6773.14282
Gröble, Sabrina; Bilger, Jana Franziska; Britt, Chantal; Kaspar, Heidi; Schmitt, Kai-Uwe (2023). Der Transport zur Hämodialyse: Was kostet er und welche Auswirkung hat er auf das Leben der Betroffenen? Bern: Berner Fachhochschule, Departement Gesundheit, Akademie-Praxis-Partnerschaft
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Gillner, Sandra; Blankart, Katharina Elisabeth; Bourgeois, Florence Tanya; Stern, Ariel Dora; Blankart, Carl Rudolf (2024). The Challenges of Regulatory Pluralism Health Policy, 149, p. 105164. Elsevier Science Direct 10.1016/j.healthpol.2024.105164
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Blankart, Katharina; Vandoros, Sotiris (2024). Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation PLOS ONE, 19(5), e0301716. Public Library of Science 10.1371/journal.pone.0301716
Goetjes, Eva; Blankart, Katharina (2024). Insurance barriers and inequalities in health care access: evidence from dual practice Health Economics Review, 14(1) BioMed Central 10.1186/s13561-024-00500-y
Gillner, Sandra; Blankart, Katharina Elisabeth; Bourgeois, Florence Tanya; Stern, Ariel Dora; Blankart, Carl Rudolf (2024). The Challenges of Regulatory Pluralism Health Policy, 149, p. 105164. Elsevier Science Direct 10.1016/j.healthpol.2024.105164
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Quiroga Gutierrez, Ana Cecilia; Boes, Stefan (2024). Bridging the gap: Experimental evidence on information provision and health insurance choices Health Economics, 33(6), pp. 1368-1386. Wiley 10.1002/hec.4820
Müller, Tobias Benjamin; Boes, Stefan (2020). Disability insurance benefits and labor supply decisions: evidence from a discontinuity in benefit awards Empirical economics, 58(5), pp. 2513-2544. Springer 10.1007/s00181-018-1587-4
Gillner, Sandra; Blankart, Katharina Elisabeth; Bourgeois, Florence Tanya; Stern, Ariel Dora; Blankart, Carl Rudolf (2024). The Challenges of Regulatory Pluralism Health Policy, 149, p. 105164. Elsevier Science Direct 10.1016/j.healthpol.2024.105164
Gröble, Sabrina; Bilger, Jana Franziska; Britt, Chantal; Kaspar, Heidi; Schmitt, Kai-Uwe (2023). Der Transport zur Hämodialyse: Was kostet er und welche Auswirkung hat er auf das Leben der Betroffenen? Bern: Berner Fachhochschule, Departement Gesundheit, Akademie-Praxis-Partnerschaft
Van Gestel, Raf; Broekman, Niels; Müller, Tobias Benjamin (2023). Surgeon supply and healthcare quality: Are revision rates for hip and knee replacements lower in hospitals that employ more surgeons? Health Economics, 32(10), pp. 2298-2321. Wiley 10.1002/hec.4727
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Müller, Tobias; Schmid, Christian; Gerfin, Michael (2022). Rents for pills: Financial incentives and physician behavior Journal of health economics, 87, p. 102711. Elsevier 10.1016/j.jhealeco.2022.102711
Gillner, Sandra; Blankart, Katharina Elisabeth; Bourgeois, Florence Tanya; Stern, Ariel Dora; Blankart, Carl Rudolf (2024). The Challenges of Regulatory Pluralism Health Policy, 149, p. 105164. Elsevier Science Direct 10.1016/j.healthpol.2024.105164
Goetjes, Eva; Blankart, Katharina (2024). Insurance barriers and inequalities in health care access: evidence from dual practice Health Economics Review, 14(1) BioMed Central 10.1186/s13561-024-00500-y
Blankart, Katharina; Vandoros, Sotiris (2024). Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation PLOS ONE, 19(5), e0301716. Public Library of Science 10.1371/journal.pone.0301716
Gröble, Sabrina; Bilger, Jana Franziska; Britt, Chantal; Kaspar, Heidi; Schmitt, Kai-Uwe (2023). Der Transport zur Hämodialyse: Was kostet er und welche Auswirkung hat er auf das Leben der Betroffenen? Bern: Berner Fachhochschule, Departement Gesundheit, Akademie-Praxis-Partnerschaft
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Gröble, Sabrina; Bilger, Jana Franziska; Britt, Chantal; Kaspar, Heidi; Schmitt, Kai-Uwe (2023). Der Transport zur Hämodialyse: Was kostet er und welche Auswirkung hat er auf das Leben der Betroffenen? Bern: Berner Fachhochschule, Departement Gesundheit, Akademie-Praxis-Partnerschaft
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Müller, Tobias; Schmid, Christian; Gerfin, Michael (2022). Rents for pills: Financial incentives and physician behavior Journal of health economics, 87, p. 102711. Elsevier 10.1016/j.jhealeco.2022.102711
Bilger, Jana Franziska; Pletscher, Mark; Müller, Tobias Benjamin (2024). Separating the wheat from the chaff: How to measure hospital quality in routine data? Health Services Research, 59(2), pp. 1-10. Wiley Online Library 10.1111/1475-6773.14282
Van Gestel, Raf; Broekman, Niels; Müller, Tobias Benjamin (2023). Surgeon supply and healthcare quality: Are revision rates for hip and knee replacements lower in hospitals that employ more surgeons? Health Economics, 32(10), pp. 2298-2321. Wiley 10.1002/hec.4727
Müller, Tobias Benjamin; Boes, Stefan (2020). Disability insurance benefits and labor supply decisions: evidence from a discontinuity in benefit awards Empirical economics, 58(5), pp. 2513-2544. Springer 10.1007/s00181-018-1587-4
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Bilger, Jana Franziska; Pletscher, Mark; Müller, Tobias Benjamin (2024). Separating the wheat from the chaff: How to measure hospital quality in routine data? Health Services Research, 59(2), pp. 1-10. Wiley Online Library 10.1111/1475-6773.14282
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218
Quiroga Gutierrez, Ana Cecilia; Boes, Stefan (2024). Bridging the gap: Experimental evidence on information provision and health insurance choices Health Economics, 33(6), pp. 1368-1386. Wiley 10.1002/hec.4820
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Schoenenberger, Lukas Klaus; Schmid, Alexander; Tanase, Radu; Beck, Mathias; Schwaninger, Markus (2021). Structural Analysis of System Dynamics Models Simulation Modelling Practice and Theory, 110, p. 102333. Elsevier 10.1016/j.simpat.2021.102333
Müller, Tobias; Schmid, Christian; Gerfin, Michael (2022). Rents for pills: Financial incentives and physician behavior Journal of health economics, 87, p. 102711. Elsevier 10.1016/j.jhealeco.2022.102711
Gröble, Sabrina; Bilger, Jana Franziska; Britt, Chantal; Kaspar, Heidi; Schmitt, Kai-Uwe (2023). Der Transport zur Hämodialyse: Was kostet er und welche Auswirkung hat er auf das Leben der Betroffenen? Bern: Berner Fachhochschule, Departement Gesundheit, Akademie-Praxis-Partnerschaft
Schoenenberger, Lukas Klaus; Schmid, Alexander; Tanase, Radu; Beck, Mathias; Schwaninger, Markus (2021). Structural Analysis of System Dynamics Models Simulation Modelling Practice and Theory, 110, p. 102333. Elsevier 10.1016/j.simpat.2021.102333
Schoenenberger, Lukas Klaus; Schmid, Alexander; Tanase, Radu; Beck, Mathias; Schwaninger, Markus (2021). Structural Analysis of System Dynamics Models Simulation Modelling Practice and Theory, 110, p. 102333. Elsevier 10.1016/j.simpat.2021.102333
Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z
Gillner, Sandra; Blankart, Katharina Elisabeth; Bourgeois, Florence Tanya; Stern, Ariel Dora; Blankart, Carl Rudolf (2024). The Challenges of Regulatory Pluralism Health Policy, 149, p. 105164. Elsevier Science Direct 10.1016/j.healthpol.2024.105164
Schoenenberger, Lukas Klaus; Schmid, Alexander; Tanase, Radu; Beck, Mathias; Schwaninger, Markus (2021). Structural Analysis of System Dynamics Models Simulation Modelling Practice and Theory, 110, p. 102333. Elsevier 10.1016/j.simpat.2021.102333
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
Van Gestel, Raf; Broekman, Niels; Müller, Tobias Benjamin (2023). Surgeon supply and healthcare quality: Are revision rates for hip and knee replacements lower in hospitals that employ more surgeons? Health Economics, 32(10), pp. 2298-2321. Wiley 10.1002/hec.4727
Blankart, Katharina; Vandoros, Sotiris (2024). Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation PLOS ONE, 19(5), e0301716. Public Library of Science 10.1371/journal.pone.0301716
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Meier, Niklaus; Pletscher, Mark (2024). Swiss Drug Pricing Model (SDPM) Ein Modell zur Berechnung wirtschaftlicher Preise neuer Therapien in der Schweiz Bern: Berner Fachhochschule Departement Gesundheit, Institut für Gesundheitsökonomie und Gesundheitspolitik
Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441
